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Summary The antitumour effects of lipoteichoic acids (LTA) extracted from Streptococcus pyogenes were
studied in comparison with other streptococcal cellular components. LTA suppressed the tumour growth of
both solid- and ascites-type MethA fibrosarcoma as did the whole cells of S. pyogenes (OK-432). No other
cellular components, such as cell wall peptidoglycan, group-specific C-carbohydrate or type-specific M
protein, suppressed the growth of MethA. LTA, but not the other cellular components, induced tumour
necrosis factor (TNF) in Propionibacterium acnes-primed mice. LTA had no direct killing effects on MethA
cells. These results indicate that LTA may be an important antitumour component of OK-432 and that one of
the antitumour mechanisms by this streptococcal preparation is the induction of TNF.
OK-432, a streptococcal preparation, has been widely used
to increase the resistance against tumours in experimental
animals and cancer patients (Kurokawa et al., 1972; Sakurai
et al., 1972). We have reported that OK-432, consisting of
the whole organisms of S. pyogenes Su strain, significantly
suppressed the growth of both ascites- and solid-type MethA
fibrosarcoma and Ehrlich carcinoma. The cytoplasmic
membrane fraction prepared from the Su strain had an
antitumour effect against the ascites variant but not against
the solid tumour. In contrast, the isolated cell wall fraction
acted as an antitumour agent against the solid tumour but
not the ascitic variant (Koshimura et al., 1977; Yamamoto et
al., 1980). These facts indicate that the antitumour principle
of streptococcal whole cells lies in the cell wall and the
cytoplasmic membrane. A possible candidate for such an
antitumour principle is lipoteichoic acids (LTA), in view of
the study by Wicken and Knox (1980) showing that LTA
transects both the cell wall and the cytoplasmic membrane.
There have been no previous reports on the antitumour
effect of LTA.
The purpose of the present study was to examine the
antitumour effects of LTA in comparison with other
streptococcal cellular components.
Materials and methods
Animals
BALB/c (female, 6-8 weeks old) and CD-1 mice (female, 6-8
weeks old) were purchased from Charles River Japan Inc.
(Atsugi, Kanagawa, Japan).
Streptococcalpreparation
Whole organisms (OK-432) A heat- and penicillin-treated
lyophilized powder of S. pyogenes Su strain (Chugai
Pharmaceutical Co., Ltd., Tokyo, Japan).
Cellular components The LTA was prepared according to
the method of Moskowitz (1966). In brief, S. pyogenes Sv (a
parent strain of Su) grown overnight in TTY broth (Hamada
and Torii, 1978) was suspended in pyrogen-free distilled
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water and then extracted with an equal volume of 95%
phenol at room temperature for 1h. The water phase
containing the LTA was separated by centrifugation at
6,000g for 30min, concentrated by evaporation under
reduced pressure, and lyophilized. The resulting crude LTA
was dissolved in 0.2M ammonium acetate at 50mgml-1 and
applied to a Sepharose 6B (Pharmacia, Uppsala Sweden)
column (2.6 x 87cm). The column was eluted with 0.2 M
ammonium acetate to separate the LTA from polyglycero-
phosphate (PGP) and nucleic acids. The LTA fraction thus
purified was lyophilized, and dissolved in pyrogen-free
0.85% NaCl solution before use. The purity of the LTA
preparation was assessed by gas-liquid chromatography, and
by chemical and immunochemical analyses as previously
described (Hamada et al., 1985). Chemical analysis showed
that the ratio of glycerol, fatty acids and alanine was
consistent with the analytical data reported by Ofek et al.
(1975). The colorimetric Limulus lysate assay with Toxicolor
Test (Seikagakukogyo, Tokyo, Japan) indicated that 1 mg of
the LTA preparation contained <280pg equivalent to a
standard reference LPS (Bacto lipopolysaccharide W derived
from Salmonella enteritidis). Other streptococcal components
were obtained as follows: Peptidoglycan was prepared from
S. pyogenes A374 according to the method described by
Schleifer and Kandler (1967). The expected amino acid
and amino sugar content characteristic of S. pyogenes
peptidoglycan was found, and other amino acids and amino
sugars were detected only in trace amounts. Group-specific
C-carbohydrate was prepared from S. pyogenes A374 by
the method of Fuller (1938). The preparation consisted
mainly of rhamnose and N-acetylglucosamine, and no
protein was detected in this preparation. An undegraded
M protein specimen was prepared from S. pyogenes Sv by
solubilization of the cell envelope (crude cell wall) fraction
with Streptomyces globisporus endo-N-acetylmuramidase (a
gift of Dr S. Kawata, Research Laboratories, Dainippon
Pharmaceutical Co., Ltd., Osaka, Japan) and by frac-
tionation with a QAE-Sephadex A-50 column (Phamacia,
Uppsala, Sweden), as described previously (Usami, 1985).
The resulting preparation was practically free of peptido-
glycan, C-carbohydrate and LTA.
In vivo antitumour effects
MethA fibrosarcoma cells (2 x 105 to 4 x 105 cells/mouse)
were inoculated i.p. (ascites) or i.d. (solid) into BALB/c mice
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(a group of 10 or 8 mice respectively). The antitumour
effects of LTA and the other streptococcal components were
determined as follows: The size of solid tumours was
measured at appropriate intervals according to the formula
length x width'12 (mm), and the mean sizes in treated and
non-treated groups were compared. For the ascites, dead and
surviving mice were recorded daily for 60 days. The increase
in life span of treated mice was calculated as a ratio of the
mean survival (in days) of treated mice to that of non-
treated mice. The completely cured mice were challenged by
i.p. injection of MethA (5x l05cells/mouse), and the
presence or absence of tumour-specific immunity was
determined 3 weeks later in terms of the rejection of
inoculated MethA.
Preparation of serum containing tumour necrosisfactor (TNF)
A group of 4 CD-I mice were injected i.p. with 1.5mg of
lyophilized formalin-killed Propionibacterium acnes. Nine
days later, the primed mice were elicited by i.v. injection of
100 jig each of test streptococcal components. Serum
specimens were taken from each group 1.5 h after the
elicitation and pooled separately. The sera were heated at
56°C for 30min to abolish nonspecific cytotoxic activity
against tumour cells, and submitted to the TNF assay below.
TNF assay
The cytostatic activity of test serum specimens against L-
929 cells (a possible TNF activity) was estimated according
to a method described previously (Yamamoto et al., 1985b).
Briefly, a suspension of L-929 cells (5 x 104cells ml-1) in
RPMI 1640 medium (GIBCO, Ohio, USA) supplemented
with 8% foetal calf serum (FCS; GIBCO) was distributed in
a 96-well microtitre plate (80,jl/well). The cells were
incubated at 37°C for 3 h in 5% C02-air. An aliquot (100pl)
of the appropriately diluted serum and 0.5 jCi (20jil/well) of
the 3H-thymidine (3H-TdR; specific activity, 25Cimmol-1;
Amersham, UK) were added to the cells in each well. After
48 h of incubation, the amount of 3H-TdR incorporated
into the cells was measured with a liquid scintilation
spectrometer.
Results
Antitumour effects ofstreptococcal components
Ten micrograms of each streptoccocal component or 100 jg
of whole organism (OK-432) were administered i.p. for 4
successive days beginning one day after the inoculation of
Meth A ascites (Figure 1). All of the 10 control mice that
were inoculated with MethA, but did not receive any test
materials, died within 14 days of tumour inoculation. By
contrast, 5 out of 10 tumour-inoculated mice receiving LTA
survived >60 days. On the 60th day, the mean survival time
was 2.8 times longer in the LTA-treated mice than that in
the non-treated mice. Of 10 tumour-inoculated mice given
streptococcal whole organisms, 6 survived. None of the
other streptococcal cellular components (peptidoglycan,
C-carbohydrate or M protein) caused any statistically
significant prolongation of survival time.
In the experiment on the suppression of solid tumour
growth (Figure 2), only LTA, among the test streptococcal
cellular components, markedly inhibited tumour growth as
compared with controls. The growth inhibition ratio in terms
of tumour size in the LTA-treated group against that in the
non-treated group was 73.4% on the 34th day (8 mice per
group). Four out of 8 LTA-treated mice were tumour-free 34
days after tumour inoculation. The whole organisms also
definitely inhibited tumour growth, but the extent of
inhibition was less than that of the LTA group (55.3%), and
there were no tumour-free mice in this group on the 34th
day.
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Figure 1 Antitumour effects of streptococcal cellular compo-
nents on MethA ascites. Test material was administered i.p. into
groups of BALB/c mice (10 per group) for 4 successive days
beginning one day after tumour inoculation. V Whole organism
(OK-432), l00jg/mouse. 0 LTA, l0pg. El Peptidoglycan, 10pg.
O C-carbohydrate, 10,jg. A M protein, 10jg. 0 Non-treated
control. Significantly different from the control on day 60:
**P<0.01.
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Figure 2 Antitumour effects of streptococcal cellular compo-
nents on solid MethA. The schedule of administration of test
materials was the same as that in Figure 1, except 8 mice were
used in each group. V Whole organisms, 100jig. 0 LTA, 10yg.
[1 Peptidoglycan, l0jg. O C-carbohydrate, l0pg. A M protein,
10jug. * Non-treated control. Significantly different from the
control on day 34: **P<0.01, *P<0.05.
The antitumour effect of LTA as a function of dose was
then studied. When 10jg LTA were injected into mice
inoculated with MethA ascites (Figure 3), 4 out of the 10
mice survived >60 days without tumour. On the 60th day,
the mean survival in the LTA-treated mice was 2.5 times
longer than that of the non-treated control mice. Adminis-
tration of either 50pg LTA definitely prolonged the survival
of tumour-inoculated mice. However, the antitumour effects
in this group were less marked than those receiving 10jg
LTA.
With the solid MethA, 10jg LTA greatly inhibited
tumour growth (77.3%) (Figure 4). Four out of 8 mice were
tumour-free when evaluated 34 days after the inoculation.
Administration of 2jg LTA also significantly suppressed
tumour growth (38.0%), but the extent of suppression was
less than that caused by 10jg LTA. In the case of 50jg
LTA, no antitumour effect was evident against solid MethA.
In the experiment described above, the mice which were
completely cured (tumour-free) after administration of LTA
71
F
v
*72 H. USAMI et al.
0-
4-
co
._0
>-
C/
Days after tumour inoculation
Figure 3 Antitumour effects of streptococcal LTA on MethA
ascites. See Figure 1 for details of the LTA administration
schedule (10 mice per group). V 50Og, E lOjig, A 2jg. 0
Non-treated control. Significantly different from the control on
day 60: **P<0.01.
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Figure 4 Antitumour effects of streptococcal LTA on solid
MethA. See Figure 1 for details of the LTA administration
schedule (8 mice per group). V 50 jg, [ 10 jig, 2 jg. * Non-
treated control. Significantly different from the control on day
34: **P<0.001, *P<0.05.
rejected rechallenge with MethA. Moreover, none of the
mice receiving test doses of LTA, showed any side effects
such as diarrhoea, ataxia or anorexia.
Effect ofLTA or other streptococcal components on Meth A
tumour cells in vitro
A possible direct cytotoxic effect of test streptococcal cellular
components, especially LTA, was checked against MethA
tumour cells in vitro.
None of test streptococcal components exhibited any
direct cytotoxic effects on MethA tumour cells at any test
dose levels (Table I).
TNF-inducing ability ofstreptococcal components
The assay of the ability of test streptococcal components to
induce TNF in the serum of the P. acnes-primed mice
showed that only LTA among the test materials caused a
high level of TNF activity. The extent of TNF induction by
100 jig LTA was comparable to that induced by g of a
reference LPA (Table II).
Table I No direct cytotoxicity of streptococcal cellular components
on MethA cells in vitro
3H-TdR uptakea
Dose Percent
Component (Cgml-1) (mean+s.d., cpm) inhibitionb
LTA 100 204,590+6,198 -5.1
2 196,025 +3,501 -0.7
0.04 188,213+6,169 -3.4
C-carbohydrate 100 196,140+1,302 -0.7
2 202,331 +3,332 -3.9
0.04 205,899 +2,330 -5.7
Peptidoglycan 100 176,027+3,696 9.6
2 199,367+2,538 -2.4
0.04 195,440+5,065 -0.4
M protein 100 207,093+ 212 -6.4
2 201,706+3,416 -3.6
0.04 195,225+4,419 -0.3
None 187,262+3,501
Various dose levels of test materials were added to MethA cells
(5 x103 cellsml-' in RPMI 1640 medium supplemented with 8%
FCS), and incubated at 37°C for 48h in 5% C02-air. Then 3H-TdR
(0.5pCi/well) was added to those reaction mixtures. After a further
6h of incubation, the incorporation of 3H-TdR into MethA cells
was measured of a liquid scintillation spectrometer. aIn triplicate.
b(l-cpm in test/cpm in 8% FCS-RPMI 1640 control) x 100 (%).
Table II The TNF-inducing ability of various streptococcal cellular
components
3H-TdR uptake inhibition
Serum dilution
Dose
Component (jig/mouse) 1/100 1/500 1/2,5001/12,500
LTA 100 97**a 96** 86** 67*
Peptidoglycan 100 5 6 -5 -4
C-carbohydrate 100 10 -6 3 -3
M protein 100 6 9 NTb NT
PGP 100 -9 10 -1 -9
Nucleic acids 100 18 -15 -23 10
LPS (S. enteritidis) 10 91** 88** 84** 77*
aSignificantly different from the control: **P<0.001, *P<0.01.
bNot tested.
Discussion
Pieringen and Ganfield (1975) reported that LTA was
anchored to bacterial cells by intercalation of the lipid end of
the molecule into the phospholipid bilayer of the cytoplasmic
membrane, with the linear PGP portion of the molecule
penetrating through the cell wall peptidoglycan and pro-
truding from the outermost cell surface. The present study
revealed that LTA definitely inhibited the growth of both
solid MethA and MethA ascites in BALB/c mice, just as
whole organisms did. In a separate study, we found that
PGP prepared by alkali treatment of LTA inhibited the
growth of solid MethA tumour, but not that of the ascites
variant. Kigoshi (1971) reported that a lipid preparation
extracted from S. pyogenes had antitumour effects on ascites-
type Ehrlich carcinoma. It was also shown that unlike whole
organisms, the cell wall had antitumour effects only on solid
tumours and the cytoplasmic membrane had antitumour
effects only on tumour ascites (Yamamoto et al. 1980).
These findings may be explained by assuming that neither
cell wall nor cytoplasmic membrane has intact LTA
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The problem is to know the mechanism by which LTA
causes tumour suppression. Direct killing of cells by LTA
was excluded in the present study (Table I). In a previous
study (Yamamoto et al., 1985a), we demonstrated that the
LTA of S. pyogenes was capable of inducing TNF in the
sera of mice primed with P. acnes, and that the serum
specimens induce haemorrhagic necrosis of pre-established
MethA tumour. Since the cytotoxic factor (CF) induced by
LTA was almost completely neutralized with anti-TNF
serum, we believe CF induced by LTA is different from
lymphotoxin (to be published). The present study
reconfirmed the above findings and showed further that
several streptococcal components other than LTA were
inactive in TNF induction (Table II). In conformity with this
finding, these streptococcal components, unlike LTA, had no
antitumour effects in vivo.
Activated cytotoxic macrophages are likely to play an
important role in host defence against neoplasia and
infections. Hamada et al. (1985) demonstrated that LTA
induced the tumoricidal macrophages in vitro. Several
research groups demonstrated that a soluble cytotoxic factor
produced from activated macrophages is similar, if not
identical, to tumour necrosis factor (Yamamoto et al., 1986;
Dryslade et al., 1987; Hashimoto et al., 1987).
The results obtained in this study indicate that LTA is
one of the antitumour components of the streptococcal
preparation, OK-432, and that one of the mechanisms of the
antitumour effect of OK-432 may be the induction of TNF.
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